<DOC>
	<DOCNO>NCT02269202</DOCNO>
	<brief_summary>To assess pharmacokinetics midazolam with/without concomitant administration crobenetine</brief_summary>
	<brief_title>Pharmacokinetics Midazolam , With Without Concomitant Administration Crobenetine Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>All participant study healthy male , range 21 50 year age bodymass index ( BMI ) within 18.5 29.9 kg/m2 Any finding medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) , deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within least one month less ten halflives respective drug enrolment study ( except substitution therapy regard thyroid gland ) Use drug might influence result trial ( within one week prior administration trial ) Participation another trial investigational drug ( within two month prior administration trial ) Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( &gt; 60 g/day ) Drug abuse Blood donation ( â‰¥ 100 mL , within four week prior administration trial ) Excessive physical activity ( within last week study ) Any laboratory value outside reference range clinical relevance</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>